Prevalence of the metabolic syndrome in a rural population in Ghana

BMC Endocrine Disorders

Table 3 Prevalence of the metabolic syndrome (MS) and its determinants by sex as defined by the IDF and NCEP ATP III criteria

Determinants of MS	Prevalence of metabolic syndrome components (%)
	IDF				NCEP ATP III
	All (206)	Male (102)	Female (104)	p	All (206)	Male (102)	Female (104)	p-values
Central Obesity	55.3	22.5	87.5	<0.001	31.1	3.9	57.7	<0.001
High BP	39.5	39.0	40.0	0.896	39.5	39.0	40.0	0.896
High FPG	12.1	11.8	12.5	0.872	5.3	5.9	4.8	0.732
Low HDL-C	42.7	32.3	52.5	0.005	42.7	32.3	52.5	0.005
High TG	10.4	9.7	11.1	0.745	10.4	9.7	11.1	0.745
MS	35.9	15.7	55.8	<0.001	15.0	5.9	24.0	<0.001

p- Values (2-tailed): comparing males and females; Central Obesity= IDF {WC≥94cm in males, ≥80cm in females} and NCEP ATPIII {WC>102cm in males, >88cm in females}.
High BP= IDF and NCEP ATPIII {SBP≥130mmHg, DBP≥85mmHg}.
High FPG= IDF {FPG≥100mg/dl}, NCEP ATPIII {FPG≥110mg/dl}.
Low HDL-C= IDF and NCEP ATPIII {HDL <40mg/dl in males, <50mg/dl in females}.
High TG= IDF and NCEP ATPIII {TG≥150mg/dl}.
MS= IDF (International Diabetes Federation) {central obesity and at least two of the following: low HDL-C (or treatment for low HDL-C), high TG (or treatment for high TG), high BP (or treatment for high BP) and high FPG (or treatment for high FPG)}.
MS= NCEP ATP III (National Cholesterol Education Program Adult Treatment Panel III) { at least three of the following: central obesity, high TG, low HDL-C, high BP and high FPG}.

ISSN: 1472-6823